Characterization of Phenotypic and Genotypic Regressors for Imaging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01148381|
Recruitment Status : Recruiting
First Posted : June 22, 2010
Last Update Posted : January 18, 2019
|First Submitted Date||June 19, 2010|
|First Posted Date||June 22, 2010|
|Last Update Posted Date||January 18, 2019|
|Study Start Date||June 4, 2010|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures||Not Provided|
|Original Primary Outcome Measures||Not Provided|
|Change History||Complete list of historical versions of study NCT01148381 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Characterization of Phenotypic and Genotypic Regressors for Imaging|
|Official Title||Characterization of Phenotypic and Genotypic Regressors|
The influence of genes on addictive and neuropsychiatric disorders is complex, especially given that multiple genes likely influence certain behaviors that are correlated with addiction. Researchers are interested in looking at the genetic information of individuals who are enrolled on National Institute for Drug Abuse studies to investigate specific genetic variants that may be related to substance abuse. Researchers will study the effects of genes on several aspects of thinking such as attention, memory, decision making, problem solving, learning, and emotional feelings, and investigate the ways in which genetic information affects addictive behaviors and substance abuse. In addition, researchers will study how genes may explain differences in imaging data in substance users.
- To collect genetic information for research on genetic aspects of addiction and substance abuse.
Objective: To determine genetic variants as well as behavioral measures across different study group populations. Results of these will be used as regressors to help explain inter-individual differences in data collected across IRP protocols.
Study Population: The study population will include 1) healthy non-smoking, non-drug dependent participants 2) healthy nicotine-dependent individuals 3) healthy individuals dependent on other commonly abused drugs 4) individuals with other psychiatric disorders and 5) treatment-seeking individuals dependent on nicotine or other commonly abused drugs. Participants must be under evaluation for another NIDA-IRP protocol, generally healthy, and age 18 or older.
Design: This study will require 1 visit (approximately 4-6 hours) to the NIDA-IRP, which may be in conjunction with another NIDA-IRP study. The characterization instruments are divided into two sections: Common Instruments and Additional Instruments. Common Instruments include instruments in common with what is done under a similar protocol at NIAAA. All participants will complete these instruments along with the blood sample, Delayed Discounting task and MRI scan. The completion of these items will define a completer of this protocol. Subjects will have the option to complete the study in multiple visits if they choose. After being consented into the study, the participant will be asked to submit a blood sample, complete various questionnaires, characterization instruments and several behavioral tasks. Blood will only be drawn once, provided there are no technical problems (such as sample damage during collection, preparation, shipping or assay) requiring a repeat draw. Participants in more than one NIDA-IRP protocol will be asked to repeat a few of the time-sensitive questionnaires in this protocol during subsequent MRI visits, as required by other IRP imaging protocols in which the subject may be participating. Data acquired in this protocol will be compared to data acquired in other NIDAIRP protocols.
Outcome Measures: The primary outcome measures in this study are the genetic, behavioral and phenotypic factors that are related to addiction. Secondary outcome measures are to compare the genetic, behavioral and phenotypic factors to imaging and behavioral data acquired across other IRP protocols.
|Study Design||Time Perspective: Other|
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Study Groups/Cohorts||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Original Estimated Enrollment||Same as current|
|Study Completion Date||Not Provided|
|Primary Completion Date||Not Provided|
All participants must be:
EXCLUSION CRITERIA: Main Study.
Exclusion criteria are limited to those in the NIDA IRP protocol for which the subject is being considered or has been consented.
Exclusion for MRI portion:
Inclusion criteria: NIDA CTN Pilot Study
All participants must:
Exclusion criteria: NIDA CTN Pilot Study
Participants may not have:
|Ages||18 Years and older (Adult, Older Adult)|
|Accepts Healthy Volunteers||Yes|
|Listed Location Countries||United States|
|Removed Location Countries|
|Other Study ID Numbers||999910457
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||National Institutes of Health Clinical Center (CC) ( National Institute on Drug Abuse (NIDA) )|
|Study Sponsor||National Institute on Drug Abuse (NIDA)|
|PRS Account||National Institutes of Health Clinical Center (CC)|
|Verification Date||October 10, 2018|